Elsevier

Bone

Volume 48, Issue 5, 1 May 2011, Pages 1008-1014
Bone

Relationship between osteoporosis and adipose tissue leptin and osteoprotegerin in patients with chronic obstructive pulmonary disease

https://doi.org/10.1016/j.bone.2011.02.017Get rights and content

Abstract

Introduction

The role of fat–bone interactions in the pathogenesis of osteoporosis in chronic obstructive pulmonary disease (COPD) is poorly understood. Our aim was to investigate expressions of leptin and osteoprotegerin (OPG) in the adipose tissue, and their relationships to osteoporosis in patients with COPD.

Methods

In 39 patients with stable COPD, bone mineral density (BMD) and body composition was assessed by Dual Energy X-Ray Absorptiometry. Serum leptin was determined by the enzyme-linked immunosorbent assay, and bone turnover markers osteocalcin and β-crosslaps by the electrochemiluminiscence immunoassays. Subcutaneous adipose tissue samples were analyzed using real-time PCR.

Results

Twenty-one patients without, and 18 with osteoporosis were enrolled (35 men; age 62.2 ± 7.3 years). Compared to patients without osteoporosis, those with the disease had significantly lower serum levels and adipose tissue expressions of leptin, in association with increased serum β-crosslaps (p = 0.028, p = 0.034, p = 0.022, respectively). Log adipose tissue leptin was inversely related to serum β-crosslaps (p = 0.015), and directly to serum leptin (p < 0.001) and to the total, femoral, and lumbar BMD and T-score (p < 0.02 for all relationships). Adipose tissue OPG expression was related to all variables of bone density except for lumbar BMD and T-score (p < 0.05 for all relationships). Log adipose tissue leptin and OPG expressions predicted femoral T-score independently of age, gender and pulmonary function (p < 0.001, adjusted R2 = 0.383; p = 0.008, adjusted R2 = 0.301, respectively). Introducing body mass (or fat mass) index into these models eliminated independent predictive value of leptin and OPG expressions.

Conclusion

Our results suggest that adipose tissue leptin and OPG expressions are related to osteoporosis in patients with COPD, and appear to act as mediators between fat mass and BMD.

Research highlights

► Osteoporosis is related to reduced leptin expression in adipose tissue (AT) in COPD. ► AT leptin expression correlates with bone mineral density (BMD) and β-crosslaps. ► AT osteoprotegerin (OPG) expression correlates with BDM and β-crosslaps. ► AT leptin and OPG predicted BMD independently of age, gender and lung function. ► Adjustments for adiposity eliminated independent predictive value of leptin and OPG.

Introduction

Chronic obstructive pulmonary disease (COPD), one of the most prevalent diseases worldwide, is characterized by poorly reversible airflow limitation that is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases, particularly cigarette smoke [1]. Nevertheless, the pathological mechanisms and clinical manifestations of COPD are not restricted only to pulmonary inflammation and airway remodeling [2]. In contrast, over the last decade, the recognition of COPD as a systemic disease developed. The best recognized systemic manifestations of COPD include systemic inflammation, cardiovascular comorbidities, osteoporosis, cachexia and muscle dysfunction, and anemia [3]. Chronic comorbidities adversely affect health outcomes in patients with COPD, including mortality.

Osteoporosis, a systemic skeletal disease characterized by low bone mineral density (BMD) and microarchitectural deterioration, is highly prevalent in patients with COPD: a recent meta-analysis of 13 studies in patients with COPD indicated the overall mean prevalence of osteoporosis of 35.1% (range 9–69%) [4]. Nevertheless, osteoporosis remains underdiagnosed and undertreated in these patients, and the underlying mechanisms remain poorly understood [5]. Proposed mechanisms that likely contribute to increased risk of low BMD in COPD include systemic inflammation, decreased physical activity owing to dyspnea, and/or other factors leading to proteolysis, reduced bone formation and increased bone resorption [6], [7]. The recently evolved novel concept of fat–bone interactions suggests that adipose tissue might profoundly affect bone formation and/or resorption [8]. A number of mechanisms for the fat–bone relationship exist, and include the contribution of adipose tissue mass to skeletal loading, the effects of fat mass on the secretion of bone active hormones from the pancreatic beta cells (including insulin and amylin), and the secretion of bone active hormones from adipocytes. Indeed, adipokines such as leptin have recently emerged as mediators of the protective effects of fat on bone tissue [9], [10].

Leptin enhances differentiation of bone marrow cells into osteoblasts, favors osteoblast activity by increasing the synthesis of new mineralized matrix and enhancement of chondrocyte maturation, and reduces osteoclast formation [11]. In addition, leptin stimulates the osteoprotegerin (OPG)-receptor activator of nuclear factor κB (RANK) pathway [12]. OPG, an anti-inflammatory protein derived from osteoblasts, inhibits osteoclastogenesis by acting as a decoy receptor to competitively inhibit RANK ligand (RANKL), and thus prevents the interaction of RANKL with its receptor RANK resulting in decreased bone resorption [13], [14]. Several studies identified positive relationships between serum leptin and bone mass in healthy individuals [15], [16], [17], [18], and in patients with mental anorexia [19] or renal osteodystrophy [20]. Moreover, OPG gene polymorphisms were related to the risk of osteoporosis [21], and the presence of autoantibodies against OPG was associated with high-turnover osteoporosis [22]. In patients with COPD, reductions in circulatory levels of leptin and OPG were recently reported [23], [24], nevertheless, potential relationships between adipose tissue leptin and OPG expressions and osteoporosis remained unexplored. Therefore, the purpose of the present study was to investigate expressions of leptin and OPG in the adipose tissue, and their relationships to osteoporosis in patients with COPD.

Section snippets

Subjects

Patients with diagnosis of COPD according to the American Thoracic Society/European Respiratory Society guidelines, free from exacerbation for ≥ 8 weeks were recruited from two out-patient clinics affiliated with the university hospital setting. The study inclusion criteria required the patients to be clinically stable, performing regular mild physical activity, and receiving an adequate and balanced diet. Exclusion criteria were use of systemic corticosteroids, treatment with long-term home

Patients

Thirty-nine patients with COPD (35 men and 4 women) were enrolled. They were generally late middle-aged (mean age 62.2 ± 7.3 years) with a mean 35.5 ± 25.7 pack years history of smoking. Patients were divided into two groups: the first was formed by 21 (53.8%) patients without, and the second by 18 (46.2%) patients with osteoporosis. Table 1 displays demographic data and body composition parameters in the two groups. The groups did not differ in any of the demographic characteristics. Nevertheless,

Discussion

The present study provides a novel observation on the role of adipose tissue in osteoporosis in patients with COPD. Our data demonstrate that COPD patients with osteoporosis have lower adipose tissue leptin expressions and lower serum leptin levels, in association with increased β-crosslaps compared to those with normal bone density. Adipose tissue leptin and OPG expressions correlated with the both, BMD variables and serum β-crosslaps levels. In addition, in multivariate analyses, leptin and

Acknowledgments

This work was supported by the Slovak Research and Development Agency under the contract No. APVV-0122-06, VEGA 1/0348/09 and VEGA 1/0227/11 of the Ministry of Education, Slovakia. The authors wish to express their gratitude to Drs. Maria Pobehova and Stefan Toth who referred patients to the study from their out-patient clinics; to Mrs. Dana Lalkovicova, the head nurse at the Pulmonary Function Laboratory, and to Mrs. Miroslava Pavuckova, the research nurse who assisted in adipose tissue

References (43)

  • J. Golledge et al.

    Relationship between CT anthropometric measurements, adipokines and abdominal aortic calcification

    Atherosclerosis

    (2008)
  • K.F. Rabe et al.

    Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary

    Am. J. Respir. Crit. Care Med.

    (2007)
  • P.J. Barnes et al.

    Systemic manifestations and comorbidities of COPD

    Eur. Respir. J.

    (2009)
  • E.F. Wouters

    Local and systemic inflammation in chronic obstructive pulmonary disease

    Proc. Am. Thorac. Soc.

    (2005)
  • L. Graat-Verboom et al.

    Current status of research on osteoporosis in COPD: a systematic review

    Eur. Respir. J.

    (2009)
  • B.P. Yawn et al.

    Co-morbidities in people with COPD: a result of multiple diseases, or multiple manifestations of smoking and reactive inflammation?

    Prim. Care Respir. J.

    (2008)
  • M. Roth

    Pathogenesis of COPD. Part III. Inflammation in COPD

    Int. J. Tuberc. Lung. Dis.

    (2008)
  • P. Magni et al.

    Molecular aspects of adipokine–bone interactions

    Curr. Mol. Med.

    (2010)
  • V. Cirmanova et al.

    The effect of leptin on bone—an evolving concept of action

    Physiol. Res.

    (2008)
  • I.R. Reid

    Relationships between fat and bone

    Osteoporos. Int.

    (2008)
  • W.R. Holloway et al.

    Leptin inhibits osteoclast generation

    J. Bone Miner. Res.

    (2002)
  • Cited by (23)

    • The impact of osteoporosis and vertebral compression fractures on mortality and association with pulmonary function in COPD: A meta-analysis

      2022, Joint Bone Spine
      Citation Excerpt :

      Data extracted from included studies are presented in Table 1. Of the 27 studies included in this review, 12 studies had a cumulative NOS score between 7–8 [14–17,19,20,24,27,28,31,33,40], indicating a low risk of bias, whereas the remaining 15 studies had NOS scores between 4–6 [18,21–23,25,26,29,30,32,34–39], indicating a high risk of bias. The scores of each study are presented in Online material, Table S1.

    • Prevalence and Risk Factors for Osteoporosis in Individuals With COPD: A Systematic Review and Meta-analysis

      2019, Chest
      Citation Excerpt :

      The mean age of the control group was 67.9 years in 12 included studies (n = 417).16,18,21-23,25,26,44,55,65,68,74 Table 1 presents the participants and study characteristics.13-76 In total, 57 of the included studies reported the prevalence of osteoporosis in COPD.

    • Circulatory osteoprotegerin is related to osteoporosis of the hip in patients with COPD

      2014, Respiratory Medicine
      Citation Excerpt :

      OPG, an anti-inflammatory protein derived from osteoblasts, is a soluble member of the tumor necrosis factor receptor superfamily that inhibits osteoclastogenesis by acting as a decoy receptor to competitively inhibit RANKL, and thus preventing the interaction of RANKL with its receptor RANK [24]. In our previous study we observed relationships between adipose tissue leptin and OPG expressions and measures of BMD among patients with COPD [4]. Nevertheless, circulatory OPG levels were not measured and, indeed, the question regarding serum OPG and osteoporosis in patients with COPD across all stages of the disease severity has not been previously approached.

    • Osteoporosis and Leptin: A Systematic Review

      2024, Iranian Journal of Public Health
    View all citing articles on Scopus
    View full text